Intersect ENT’s (XENT) “Buy” Rating Reiterated at Guggenheim

Intersect ENT (NASDAQ:XENT)‘s stock had its “buy” rating reiterated by equities research analysts at Guggenheim in a research report issued on Friday. They presently have a $41.00 price objective on the medical equipment provider’s stock. Guggenheim’s target price would suggest a potential upside of 28.73% from the company’s previous close.

Other equities analysts also recently issued research reports about the stock. Northland Securities reissued a “hold” rating and issued a $25.00 price objective on shares of Intersect ENT in a research note on Friday, November 3rd. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $35.00 price target on shares of Intersect ENT in a report on Tuesday, August 22nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $36.00 price target on shares of Intersect ENT in a report on Monday. BidaskClub lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Finally, BTIG Research reaffirmed a “hold” rating on shares of Intersect ENT in a report on Tuesday, November 7th. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $33.38.

Intersect ENT (NASDAQ:XENT) opened at $31.85 on Friday. Intersect ENT has a 12 month low of $11.00 and a 12 month high of $34.40.

Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.05. The company had revenue of $22.31 million during the quarter, compared to the consensus estimate of $21.53 million. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. Intersect ENT’s revenue for the quarter was up 20.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. research analysts anticipate that Intersect ENT will post -0.63 earnings per share for the current fiscal year.

In other Intersect ENT news, General Counsel David Aaron Lehman sold 36,000 shares of the company’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $32.75, for a total value of $1,179,000.00. Following the sale, the general counsel now directly owns 45,000 shares of the company’s stock, valued at $1,473,750. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Frederic H. Moll sold 6,700 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $28.77, for a total transaction of $192,759.00. Following the completion of the sale, the director now directly owns 247,124 shares in the company, valued at $7,109,757.48. The disclosure for this sale can be found here. Insiders have sold 129,838 shares of company stock worth $3,892,610 over the last three months. Corporate insiders own 13.70% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Legal & General Group Plc boosted its holdings in Intersect ENT by 3.8% in the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after purchasing an additional 255 shares during the last quarter. Voya Investment Management LLC raised its position in shares of Intersect ENT by 9.7% in the second quarter. Voya Investment Management LLC now owns 12,724 shares of the medical equipment provider’s stock worth $356,000 after acquiring an additional 1,128 shares during the period. Rhumbline Advisers raised its position in shares of Intersect ENT by 5.9% in the second quarter. Rhumbline Advisers now owns 29,396 shares of the medical equipment provider’s stock worth $822,000 after acquiring an additional 1,625 shares during the period. EAM Investors LLC raised its position in shares of Intersect ENT by 1.1% in the third quarter. EAM Investors LLC now owns 164,267 shares of the medical equipment provider’s stock worth $5,117,000 after acquiring an additional 1,776 shares during the period. Finally, Teachers Advisors LLC raised its position in shares of Intersect ENT by 3.5% in the first quarter. Teachers Advisors LLC now owns 61,858 shares of the medical equipment provider’s stock worth $1,061,000 after acquiring an additional 2,084 shares during the period. 86.31% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://ledgergazette.com/2017/12/15/intersect-ents-xent-buy-rating-reiterated-at-guggenheim.html.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply